Outcomes of COVID-19 and risk factors in patients with cancer

Sengar, Manju; Chinnaswamy, Girish; Ranganathan, Priya; Ashok, Apurva; Bhosale, Shilpushp J; Biswas, Sanjay; Chaturvedi, Pankaj; Dhamne, Chetan; Divatia, Jigeeshu V.; D’Sa, Karishma; Jain, Hasmukh; Laskar, Sarbani Ghosh; Moulik, Nirmalya Roy; Mummudi, Naveen; Nair, Sindhu S.; Nayak, Lingaraj; Nayak, Prakash; Patkar, Shraddha; Pawaskar, Preeti; Ramaswamy, Anant; Shetty, Omshree; Singh, Arjun; Epari, Sridhar; Thorat, Jayashree; Badwe, Rajendra; Pramesh, C.S.

doi:10.1038/s43018-022-00363-4

Cited by 13 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study also showed that patients with underlying malignancy had significantly more complications with CAP due to COVID-19 than those with non-COVID-19 CAP. Our results are concordant with those of previous studies demonstrating an increased risks of COVID-19-related severe events and mortality rates in patients with cancer [ 36 , 37 , 38 , 39 ]. Furthermore, the independent factors reported to be associated with increased 30-day mortality in cancer patients with COVID-19 included older age, male sex, former smoking habit, presence of comorbidities, an Eastern Cooperative Oncology Group performance status of 2 or higher, and receipt of azithromycin plus hydroxychloroquine [ 36 ].…”

Section: Discussionsupporting

confidence: 93%

“…Furthermore, the independent factors reported to be associated with increased 30-day mortality in cancer patients with COVID-19 included older age, male sex, former smoking habit, presence of comorbidities, an Eastern Cooperative Oncology Group performance status of 2 or higher, and receipt of azithromycin plus hydroxychloroquine [ 36 ]. A recent publication from India also demonstrated that advancing age, smoking history, concurrent comorbidities, and palliative intent of treatment were independently associated with severe COVID-19 or death [ 39 ]. In addition, patients with cancer might have a higher risk of COVID-19 than those without cancer in Chinese populations [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP

Tongsengkee

Surasombatpattana

Tanomkiat

et al. 2023

JCM

View full text Add to dashboard Cite

The study was conducted from October 2020 to March 2022 in a province in southern Thailand. The inpatients with community-acquired pneumonia (CAP) and more than 18 years old were enrolled. Of the 1511 inpatients with CAP, COVID-19 was the leading cause, accounting for 27%. Among the patients with COVID-19 CAP, mortalities, mechanical ventilators, ICU admissions, ICU stay, and hospital costs were significantly higher than of those with non-COVID-19 CAP. Household and workplace contact with COVID-19, co-morbidities, lymphocytopenia and peripheral infiltration in chest imaging were associated with CAP due to COVID-19. The delta variant yielded the most unfavorable clinical and non-clinical outcomes. While COVID-19 CAP due to B.1.113, Alpha and Omicron variants had relatively similar outcomes. Among those with CAP, COVID-19 infection as well as obesity, a higher Charlson comorbidity index (CCI) and APACHE II score were associated with in-hospital mortality. Among those with COVID-19 CAP, obesity, infection due to the Delta variant, a higher CCI and higher APACHE II score were associated with in-hospital mortality. COVID-19 had a great impact on the epidemiology and outcomes of CAP.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP

Tongsengkee

Surasombatpattana

Tanomkiat

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Patients with cancer have higher rates of severe disease and fatality after COVID-19 than the general population. In a recent meta-analysis (26 studies, 23,736 patients), Venkatesulu et al ( 27 ) found nearly threefold higher odds of death in cancer patients affected by COVID-19 than in those without cancer ( 28 ). According to the Global Cancer Observatory Database, nearly 19.3 million new cancer cases have been declared in 2020 globally ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/ Pfizer) Vaccination on Oncologic <sup>18</sup>F-FDG PET/CT Studies

Şan¹,

Alagöz²

2022

Mirt

View full text Add to dashboard Cite

Objectives: BioNTech (Pfizer) and CoronaVac (Sinovac) vaccines are two of the most administered coronavirus disease-2019 (COVID-19) vaccines worldwide. Vaccination against severe acute respiratory syndrome-coronavirus-2 has caused a diagnostic challenge in oncological 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) studies. The aim of our study was to evaluate the 18 F-FDG PET/CT findings of the two most commonly administered vaccines worldwide. Methods: Patients over 18 years old who underwent 18 F-FDG PET/CT for oncological purposes in our institution between January 13, 2021 and January 31, 2022, who received a single or second dose of the BioNTech or CoronaVac vaccines in the last two months, were included in the study. Descriptive analyses were presented as mean, standard deviation, frequency and ratio. Additionally, chi-square test was used to analyze categorical variables. Results: Ipsilateral deltoid muscle hypermetabolism was observed in 6.9% (n=15) and 14.3% (n=22) patients who received CoronaVac and BioNTech vaccines, respectively. Ipsilateral axillary lymph node hypermetabolism was observed in 11% (n=24) and 41.6% (n=64) patients who received CoronaVac and BioNTech vaccines, respectively. Synchronous deltoid muscle and axillary lymph node hypermetabolism was observed in 4.14% (n=9) and 12.33% (n=19) patients who received CoronaVac and BioNTech vaccines, respectively. Significant differences were detected between CoronaVac and BioNTech vaccines in terms of ipsilateral deltoid muscle hypermetabolism, ipsilateral axillary lymph node hypermetabolism and synchronous deltoid muscle and axillary lymph node hypermetabolism (p<0.05). Conclusion: COVID-19 vaccination may result in ipsilateral axillary lymph node hypermetabolism, ipsilateral deltoid muscle hypermetabolism, or synchronous deltoid muscle and axillary lymph node hypermetabolism with different frequencies depending on the type of vaccination. Although synchronous deltoid muscle and axillary lymph node hypermetabolism can reduce misinterpretation of 18 F-FDG PET/CT, to avoid misinterpretation, it is important to question the vaccination history during ongoing COVID-19 vaccination process.

show abstract

“…While it partially controlled viral spreading and kept health systems functioning, the magnitude of the impact of the pandemic has varied very differently between countries ( Bedford et al, 2020 ) ( Chen et al, 2021 ) due to underlying local differences such as specific governmental policy responses. Nevertheless, some of those restrictions, such as lockdowns, revealed to be economically and socially unsustainable when applied for long periods of time ( Mathieu et al, 2020 ), with critical side effects with long-lasting societal impacts such as limited access to education ( Hoofman and Secord, 2021 ) and health treatments of other origin ( Pley et al, 2021 ; Sengar et al, 2022 ).…”

Section: Sars-cov-2: An Emerging Threat Of International Concernmentioning

confidence: 99%